BUY Aurobindo Pharma — CLSA, 07 Aug 2026

BUYAurobindo Pharma

Aurobindo Pharma share price target & all analyst calls

byCLSAHorizon: NA (inferred 1 year)7 Aug 2026via CNBC Awaaz.

Entry₹1,580.1Inferred

Target₹1,600

Total upside +1.26%

Stop lossNot given

Exit₹1,6007 Aug 2026, 12:08 pm

Target hit+1.26%0.00%upside left

Follow CLSA for new calls(100% target hit, 24 closed calls)Get alerts Watch AUROPHARMA for new buy/sell callsGet alerts See 11 active Long-term calls on AUROPHARMA See 274 active Long-term picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

Frozen at close · 7 Aug 2026

20 supporting8 neutral4 opposing

Supports the BUY call (20)

Aurobindo Pharma rises 3% after Q1 beat; HDFC Securities retains 'Add', Axis Securities cuts to 'Hold'

NewsGoogle News·7 Aug · today

Hold Aurobindo Pharma; target of Rs 1600: Prabhudas Lilladher

NewsGoogle News·7 Aug · today

5 other SEBI-registered advisors have active long-term BUY calls on this stock, with 4 issued in the last 14 days

Advisor consensus · same horizon·7 Aug · today

Aurobindo Pharma Shares Tumble 2% Despite Q1 Profit Jump, Double Digit Revenue Guidance For FY27

NewsNdtv-Profit·6 Aug · yesterday

Aurobindo Pharma's Q1 Margin Story Improves; Macquarie Says Growth Picture Is Still Uneven

NewsNdtv-Profit·6 Aug · yesterday

Neutral / worth noting (8)

Aurobindo Pharma has announced its unaudited financial results for the first quarter ended June 30, 2026. The company has provided a press release detailing these results.

NSE · Press Release·5 Aug · yesterday

Aurobindo Pharma Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.

NSE · Outcome of Board Meeting·5 Aug · yesterday

Aurobindo Pharma signs licensing pact with Merck to supply generic HIV drug in 129 countries

NewsCnbc-Tv18·24 Jul · 2w ago

Aurobindo Pharma arm Apitoria to acquire 80% stake in A1 Biochem Group for $17 million

NewsCnbc-Tv18·23 Jul · 2w ago

Aurobindo Pharma Limited has incorporated a new wholly owned stepdown subsidiary in Indonesia.

NSE · Acquisition·10 Jul · 4w ago

Weighs against the BUY call (4)

1 advisor has an active short-term SELL call on this stock, issued in the last 14 days

Advisor consensus · adjacent horizon·6 Aug · yesterday

1 other SEBI-registered advisor has an active long-term SELL call on this stock, issued in the last 14 days

Advisor consensus · same horizon·27 Jul · 2w ago

US tariff threat drags Nifty Pharma 1.4% lower; Lupin, Auropharma lead decline

NewsHbl·22 Jul · 2w ago

Pharma stocks decline; Aurobindo Pharma down over 4%

NewsHbl·22 Jul · 2w ago

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Aurobindo Pharma

All analyst calls on Aurobindo Pharma

More from CLSA

Every call and its outcome